Global Value Access & Policy, Director
expert with more than 10 years of experience, in Pharma and Biotechnology industries in Rare Disease. Market Access leader in building local and regional market access functions, integrating market access into clinical development process, optimizing product value proposition throughout life cycle, and delivering pricing and market access successes. Responsible for all succeed strategies to include Tafamidis-Vyndaqel at the Federal Reimbursement, recently approved in january 2018. The expectation is 5k patients that will get access to treatment. Solid track records of making impacts to business. Most recently, developed market access strategies to portfolio and pipeline function from scratch for Pfizer Rare Disease Business Unit. focus on building capabilities, trust and credibility with internal and external stakeholders, on development of a shared vision.